دورية أكاديمية
Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy.
| العنوان: | Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy. |
|---|---|
| المؤلفون: | De Silva MK; From the Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Chan DLH, Bernard EJ, Conner AJ; From the Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Mascall SL; From the Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia., Bailey DL, Roach PJ, Clarke SJ, Diakos CI, Pavlakis N, Schembri G |
| المصدر: | Pancreas [Pancreas] 2024 Aug 01; Vol. 53 (7), pp. e560-e565. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8608542 Publication Model: Print Cited Medium: Internet ISSN: 1536-4828 (Electronic) Linking ISSN: 08853177 NLM ISO Abbreviation: Pancreas Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: [New York, N.Y.] : Raven Press, [c1986- |
| مواضيع طبية MeSH: | Neuroendocrine Tumors*/pathology , Neuroendocrine Tumors*/radiotherapy , Neuroendocrine Tumors*/diagnostic imaging , Neuroendocrine Tumors*/metabolism , Neuroendocrine Tumors*/mortality , Fluorodeoxyglucose F18* , Octreotide*/analogs & derivatives , Octreotide*/therapeutic use , Radiopharmaceuticals* , Positron-Emission Tomography*/methods , Tumor Burden* , Organometallic Compounds*/therapeutic use, Humans ; Male ; Middle Aged ; Female ; Retrospective Studies ; Aged ; Prognosis ; Adult ; Receptors, Peptide/metabolism ; Glycolysis ; Aged, 80 and over ; Pancreatic Neoplasms/pathology ; Pancreatic Neoplasms/radiotherapy ; Pancreatic Neoplasms/diagnostic imaging ; Pancreatic Neoplasms/mortality ; Progression-Free Survival ; Treatment Outcome |
| مستخلص: | Objective: We investigated metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on pre-treatment FDG-PET as prognostic markers for survival in patients with metastatic neuroendocrine neoplasms (NENs) receiving peptide receptor radionuclide therapy (PRRT). Methods: A retrospective review of patients with metastatic NENs receiving PRRT was undertaken. Pre-treatment FDG-PET images were analyzed and variables collected included MTV and TLG (dichotomized by median into high vs low). Main Outcomes were overall survival (OS) and progression-free survival (PFS) by MTV and TLG (high vs low). Results: One hundred five patients were included. Median age was 64 years (50% male). Main primary NEN sites were small bowel (43.8%) and pancreas (40.0%). Median MTV was 3.8 mL and median TLG was 19.9. Dichotomization formed identical cohorts regardless of whether MTV or TLG were used. Median OS was 72 months; OS did not differ based on MTV/TLG high versus low (47.4 months vs not reached; hazard ratio, 0.43; 95% confidence interval [CI], 0.18-1.04; P = 0.0594). Median PFS was 30.4 months; PFS differed based on MTV/TLG high versus low (21.6 months vs 45.7 months; hazard ratio, 0.35; 95% CI, 0.19-0.64; P = 0.007). Conclusions: Low MTV/TLG on pre-treatment FDG-PET was associated with longer PFS in metastatic NEN patients receiving PRRT. Competing Interests: The authors declare no conflict of interest. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342. Chauhan A, Yu Q, Ray N, et al. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget. 2018;9:19245–19254. Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589–597. Chan DL, Ferone D, Albertelli M, et al. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETs: a systematic review. Endocrine. 2017;57:366–375. Pavel M, O'Toole D, Costa F, et al. ENETS consensus guidelines update for the Management of Distant Metastatic Disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–185. Chan DL, Clarke SJ, Diakos CI, et al. Prognostic and predictive biomarkers in neuroendocrine tumours. Crit Rev Oncol Hematol. 2017;113:268–282. Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35:853–860. Campana D, Ambrosini V, Pezzilli R, et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51:353–359. Kratochwil C, Stefanova M, Mavriopoulou E, et al. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine Tumors. Mol Imaging Biol. 2015;17:313–318. Binderup T, Knigge U, Loft A, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med. 2010;51:704–712. Bahri H, Laurence L, Edeline J, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014;55:1786–1790. Garin E, Le Jeune F, Devillers A, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50:858–864. Johnbeck CB, Knigge U, Langer SW, et al. Prognostic value of 18F-FLT PET in patients with neuroendocrine neoplasms: a prospective head-to-head comparison with 18F-FDG PET and Ki-67 in 100 patients. J Nucl Med. 2016;57:1851–1857. Ezziddin S, Adler L, Sabet A, et al. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system. J Nucl Med. 2014;55:1260–1266. Chan DL, Bernard EJ, Schembri G, et al. High metabolic tumour volume on 18-fluorodeoxyglucose positron emission tomography predicts poor survival from neuroendocrine neoplasms. Neuroendocrinology. 2020;110(11-12):950–958. Son SH, Lee SW, Jeong SY, et al. Whole-body metabolic tumor volume, as determined by (18)F-FDG PET/CT, as a prognostic factor of outcome for patients with breast cancer who have distant metastasis. AJR Am J Roentgenol. 2015;205:878–885. Dosani M, Yang R, McLay M, et al. Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy. Curr Oncol. 2019;26:e57–e63. Kim HS, Choi JY, Choi DW, et al. Prognostic value of volume-based metabolic parameters measured by (18)F-FDG PET/CT of pancreatic neuroendocrine tumors. Nucl Med Mol Imaging. 2014;48:180–186. Satoh K, Sadowski SM, Dieckmann W, et al. 18F-FDG PET/CT volumetric parameters are associated with tumor grade and metastasis in pancreatic neuroendocrine tumors in von Hippel-Lindau disease. Ann Surg Oncol. 2016;23(Suppl 5):714–721. Mapelli P, Partelli S, Salgarello M, et al. Risk stratification in pancreatic neuroendocrine tumours: the role of combined 68Ga-DOTATOC and 18F-FDG PET/CT. J Nucl Med. 2018;59(supplement 1):1303–1303. Thang SP, Lung MS, Kong G, et al. Peptide receptor radionuclide therapy (PRRT) in European neuroendocrine tumour society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) — a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging. 2018 Feb;45:262–277. Van der Zwan W, Wyld D, Brabander T, et al. A randomized controlled study comparing treatment of gastro-entero-pancreatic neuroendocrine tumors (GEPNET) with 177Lu-DOTATATE alone and in combination with capecitabine. In: Proceedings of ENETS 2018 [Internet]. Barcelona, Spain; [cited 2021 Mar 12]. p. Abst #2286. Available at: https://www.enets.org/a-randomized-controlled-study-comparing-treatment-of-gastro-entero-pancreatic-neuroendocrine-tumors-gepnet-with-177lu-dotatate-alone-and-in-combination-with-capecitabine.html. Accessed December 23, 2021. Pavlakis N, Ransom DT, Wyld D, et al. Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide (CAPTEM)—first results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS). J Clin Oncol. 2020;38(15_suppl):4608–4608. Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543:65–71. Chan DL, Pavlakis N, Schembri GP, et al. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7:1149–1158. |
| المشرفين على المادة: | 0Z5B2CJX4D (Fluorodeoxyglucose F18) RWM8CCW8GP (Octreotide) 0 (Radiopharmaceuticals) 0 (Organometallic Compounds) 0 (Receptors, Peptide) AE221IM3BB (lutetium Lu 177 dotatate) |
| تواريخ الأحداث: | Date Created: 20240710 Date Completed: 20240710 Latest Revision: 20240710 |
| رمز التحديث: | 20240711 |
| DOI: | 10.1097/MPA.0000000000002336 |
| PMID: | 38986077 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1536-4828 |
|---|---|
| DOI: | 10.1097/MPA.0000000000002336 |